Annual Congress Stockholm 2002

Saturday, 14.09.2002
Sunday, 15.09.2002
Monday, 16.09.2002
Tuesday, 17.09.2002
Wednesday, 18.09.2002

Citations should be made in the following way: Authors. Title. Eur Respir J 2002; 20: Suppl. 38, abstract number.

Material from 2002:

3388 Abstracts
6 Slide presentations
5 Handouts

Material from 2002: Show

Lung cancer: treatment

Oral Presentation
Chairs: J-P. Sculier (Brussels, Belgium), N. Hara (Fukuoka, Japan)

Download all media

The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting R. Stephens, N. H. Gower, V. Napp, R. M. Rudd, S. G. Spiro, H. Thorpe (London, United Kingdom)
Induction chemotherapy and simultaneous radiochemotherapy or radiotherapy in inoperable NSCLC (stage IIIA/IIIB) R. M. Huber, M. Schmidt, M. Flentje, B. Pöllinger, J. Willner, K. Ulm, H. Gosse, BROCAT Group (Munich, Würzburg, Leipzig, Germany)
Gemcitabine and carboplatin (GC) versus mitomycin, ifosfamide and cisplatin (MIP): a phase III randomised comparison in stage IIIb or IV non-small cell lung cancer (NSCLC) N. H. Gower, R. M. Rudd, L. E. James, W. Gregory, T. Eisen, S. M. Lee, P. G. Harper, S. G. Spiro (London, United Kingdom)
Two randomised, double-blind studies of ZD1839 in 425 patients with pretreated advanced non-small-cell lung cancer (IDEAL 1 and IDEAL 2) J. Vansteenkiste, R. Natale, G. Giaccone, R. Herbst, A. Feyereislova, A. Kay, M. Wolf (Leuven, Belgium; Beverly Hills, Houston, Wilmington, United States Of America; Amsterdam, The Netherlands; Macclesfield, United Kingdom)
A randomised phase III comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC) L. E. James, R. M. Rudd, N. H. Gower, W. Gregory, S. M. Lee, T. Eisen, P. Ellis, D. Gilligan, D. Ferry, S. G. Spiro (London, Cambridge, Birmingham, United Kingdom)
A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer J. P. Sculier, J. J. Lafitte, J. Lecomte, T. Berghmans, J. Thiriaux, O. Van Cutsem, A. Eremidis, V. Ninane, M. Paesmans, J. Klastersky (Brussels, Charleroi, Namur, Belgium; Lille, France; Athens, Greece)
Chemoembolization of the lung improves tumor control in a rat model: first experimental results P. Schneider, S. Kampfer, T. Foitzik, H. J. Buhr (Berlin, Germany)
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment C. M. Richardson, D. E. B. Swinson, D. Richardson, C. Allen, K. J. O'Byrne (Leicester, United Kingdom)